Evaluation of topical cysteamine therapy in the Ctns-/- knockout mouse using in vivo confocal microscopy

Molecular Vision

Volumn 17, Issue , 2011, Pages 2649-2654

  Simpson, Jennifer L ^a   Nien, Chyong Jy ^a   Flynn, Kevin J ^a   Jester, James V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTINE; EYE DROPS; MERCAPTAMINE;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORNEA DISEASE; CORNEA NEOVASCULARIZATION; CORNEAL CYSTINOSIS; CRYSTAL VOLUME INDEX; CRYSTALLIZATION; DISEASE COURSE; DRUG EFFICACY; DRUG SCREENING; IN VIVO STUDY; KERATITIS; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OCULAR FIBROSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCAR; SENSITIVITY AND SPECIFICITY; VISUAL SYSTEM PARAMETERS;

ADMINISTRATION, OPHTHALMIC; AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; ANIMALS; CORNEA; CRYSTALLIZATION; CYSTEAMINE; CYSTINE; CYSTINOSIS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; OPHTHALMIC SOLUTIONS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 83055174008     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Anikster Y, Shotelersuk V, Gahl WA. CTNS mutations in patients with cystinosis. Hum Mutat 1999; 14:454-8. [PMID: 10571941]
2. Attard M, Jean G, Forestier L, Cherqui S, van't Hoff W, Broyer M, Antignac C, Town M. Severity of phenotype in cystinosis varies with mutations in the CTNS gene: predicted effect on the model of cystinosin. Hum Mol Genet 1999; 8:2507-14. [PMID: 10556299]
3. Kalatzis V, Cohen-Solal L, Cordier B, Frishberg Y, Kemper M, Nuutinen EM, Legrand E, Cochat P, Antignac C. Identification of 14 novel CTNS mutations and characterization of seven splice site mutations associated with cystinosis. Hum Mutat 2002; 20:439-46. [PMID: 12442267]
4. Shotelersuk V, Larson D, Anikster Y, McDowell G, Lemons R, Bernardini I, Guo J, Thoene J, Gahl WA. CTNS mutations in an American-based population of cystinosis patients. Am J Hum Genet 1998; 63:1352-62. [PMID: 9792862]
5. Cantani A, Giardini O, D'Eufemia P. The treatment of cystinosis with cysteamine. Ann Pediatr (Paris) 1991; 38:440. [PMID: 1929112]
6. Cantani A, Giardini O, Ciarnella Cantani A. Nephropathic cystinosis: ineffectiveness of cysteamine therapy for ocular changes. Am J Ophthalmol 1983; 95:713-4. [PMID: 6846466]
7. Gahl WA, Kuehl EM, Iwata F, Lindblad A, Kaiser-Kupfer MI. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Mol Genet Metab 2000; 71:100-20. [PMID: 11001803]
8. Gahl WA, Thoene JG, Schneider JA, O'Regan S, Kaiser-Kupfer MI, Kuwabara T. NIH conference. Cystinosis: progress in a prototypic disease. Ann Intern Med 1988; 109:557-69. [PMID: 3048161]
9. Tsilou E, Zhou M, Gahl W, Sieving PC, Chan CC. Ophthalmic manifestations and histopathology of infantile nephropathic cystinosis: report of a case and review of the literature. Surv Ophthalmol 2007; 52:97-105. [PMID: 17212992]
10. Tsilou ET, Rubin BI, Reed G, Caruso RC, Iwata F, Balog J, Gahl WA, Kaiser-Kupfer MI. Nephropathic cystinosis: posterior segment manifestations and effects of cysteamine therapy. Ophthalmology 2006; 113:1002-9. [PMID: 16603246]
11. Tsilou ET, Rubin BI, Reed GF, Iwata F, Gahl W, Kaiser-Kupfer MI. Age-related prevalence of anterior segment complications in patients with infantile nephropathic cystinosis. Cornea 2002; 21:173-6. [PMID: 11862089]
12. Gahl WA, Reed GF, Thoene JG, Schulman JD, Rizzo WB, Jonas AJ, Denman DW, Schlesselman JJ, Corden BJ, Schneider JA. Cysteamine therapy for children with nephropathic cystinosis. N Engl J Med 1987; 316:971-7. [PMID: 3550461]
13. Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med 2002; 347:111-21. [PMID: 12110740]
14. Iwata F, Kaiser-Kupfer MI. Ocular manifestations of metabolic disorders. Curr Opin Ophthalmol 1994; 5:79-83. [PMID: 10150832]
15. Gahl WA. Early oral cysteamine therapy for nephropathic cystinosis. Eur J Pediatr 2003; 162:S38-41. [PMID: 14610675]
16. Gahl WA, Balog JZ, Kleta R. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. Ann Intern Med 2007; 147:242-50. [PMID: 17709758]
17. Kleta R, Gahl WA. Pharmacological treatment of nephropathic cystinosis with cysteamine. Expert Opin Pharmacother 2004; 5:2255-62. [PMID: 15500372]
18. Thoene JG, Oshima RG, Crawhall JC, Olson DL, Schneider JA. Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo. J Clin Invest 1976; 58:180-9. [PMID: 932205]
19. Tsilou ET, Thompson D, Lindblad AS, Reed GF, Rubin B, Gahl W, Thoene J, Del Monte M, Schneider JA, Granet DB, Kaiser-Kupfer MI. A multicentre randomised double masked clinical trial of a new formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis. Br J Ophthalmol 2003; 87:28-31. [PMID: 12488257]
20. Markello TC, Bernardini IM, Gahl WA. Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med 1993; 328:1157-62. [PMID: 8455682]
21. Hsuan JD, Harding JJ, Bron AJ. The penetration of topical cysteamine into the human eye. J Ocul Pharmacol Ther 1996; 12:499-502. [PMID: 8951686]
22. Jones NP, Postlethwaite RJ, Noble JL. Clearance of corneal crystals in nephropathic cystinosis by topical cysteamine 0.5%. Br J Ophthalmol 1991; 75:311-2. [PMID: 2036352]
23. Kaiser-Kupfer MI, Fujikawa L, Kuwabara T, Jain S, Gahl WA. Removal of corneal crystals by topical cysteamine in nephropathic cystinosis. N Engl J Med 1987; 316:775-9. [PMID: 3821824]
24. Cherqui S, Kalatzis V, Forestier L, Poras I, Antignac C. Identification and characterisation of the murine homologue of the gene responsible for cystinosis, Ctns. BMC Genomics 2000; 1:2. [PMID: 11121245]
25. Cherqui S, Sevin C, Hamard G, Kalatzis V, Sich M, Pequignot MO, Gogat K, Abitbol M, Broyer M, Gubler MC, Antignac C. Intralysosomal cystine accumulation in mice lacking cystinosin, the protein defective in cystinosis. Mol Cell Biol 2002; 22:7622-32. [PMID: 12370309]
26. Forestier L, Jean G, Attard M, Cherqui S, Lewis C, van't Hoff W, Broyer M, Town M, Antignac C. Molecular characterization of CTNS deletions in nephropathic cystinosis: development of a PCR-based detection assay. Am J Hum Genet 1999; 65:353-9. [PMID: 10417278]
27. Kalatzis V, Cherqui S, Antignac C, Gasnier B. Cystinosin, the protein defective in cystinosis, is a H(+)-driven lysosomal cystine transporter. EMBO J 2001; 20:5940-9. [PMID: 11689434]
28. Kalatzis V, Serratrice N, Hippert C, Payet O, Arndt C, Cazevieille C, Maurice T, Hamel C, Malecaze F, Antignac C, Muller A, Kremer EJ. The ocular anomalies in a cystinosis animal model mimic disease pathogenesis. Pediatr Res 2007; 62:156-62. [PMID: 17597652]
29. Kalatzis V, Cherqui S, Jean G, Cordier B, Cochat P, Broyer M, Antignac C. Characterization of a putative founder mutation that accounts for the high incidence of cystinosis in Brittany. J Am Soc Nephrol 2001; 12:2170-4. [PMID: 11562417]
30. Kalatzis V, Nevo N, Cherqui S, Gasnier B, Antignac C. Molecular pathogenesis of cystinosis: effect of CTNS mutations on the transport activity and subcellular localization of cystinosin. Hum Mol Genet 2004; 13:1361-71. [PMID: 15128704]
31. Simpson J, Nien CJ, Flynn KJ, Cherqui S, Jester JV. Quantitative in vivo and ex vivo confocal microscopy analysis of corneal cystine crystals in the Ctns-/-knockout mouse. Mol Vis 2011; 17:2212-20. [PMID: 21897743]
32. Kaiser-Kupfer MI, Gazzo MA, Datiles MB, Caruso RC, Kuehl EM, Gahl WA. A randomized placebo-controlled trial of cysteamine eye drops in nephropathic cystinosis. Arch Ophthalmol 1990; 108:689-93. [PMID: 2185723]
33. MacDonald IM, Noel LP, Mintsioulis G, Clarke WN. The effect of topical cysteamine drops on reducing crystal formation within the cornea of patients affected by nephropathic cystinosis. J Pediatr Ophthalmol Strabismus 1990; 27:272-4. [PMID: 2246744]
34. Bozdaǧ S, Gumus K, Gumus O, Unlu N. Formulation and in vitro evaluation of cysteamine hydrochloride viscous solutions for the treatment of corneal cystinosis. Eur J Pharm Biopharm 2008; 70:260-9. [PMID: 18590953]
35. Buchan B, Kay G, Heneghan A, Matthews KH, Cairns D. Gel formulations for treatment of the ophthalmic complications in cystinosis. Int J Pharm 2010; 392:192-7. [PMID: 20382212]